The growing adoption of GLP-1 medications is driving a shift in the food, beverage, and supplement industries to support consumers on these therapies and when they transition off them. Industry experts highlight how these drugs boost demand for holistic metabolic wellness and how companies can respond with solutions to enhance GLP-1s. Nutrition Insight discusses opportunities for innovations with Gnosis by Lesaffre, Kerry, Saanroo, and ADM. Silvia Pisoni, global operational marketing director at Gnosis by Lesaffre, says that GLP-1 receptor agonists (RAs) represent not only the epitome of a market disruptor but also a paradigm shift in how obesity and overweight are treated.
